Manila, Philippines – Takeda Healthcare Philippines Inc. proudly introduces an anti-inhibitor coagulant complex to the Philippine market, offering Filipino patients with hemophilia and related bleeding disorders a significant breakthrough in treatment options.
Hemophilia affects around 400,000 people globally, including over 10,000 in the Philippines, significantly impacting their quality of life and requiring ongoing medical care. Takeda’s medicine has a legacy of over 40 years in treating Hemophilia A and B with inhibitors, is the only bypassing agent targeting all three pathways, with 81% efficacy in controlling bleeding within six hours. It has also been included in the Philippines’ priority Health Technology Assessment list to improve patient access.
“We are aware that affordability remains a pressing concern for many patients, and we are pleased to share that we are making this treatment 70% more affordable than the other available treatment options,” said Loreann Villanueva, Country Manager of Takeda in the Philippines. “This milestone is part of our commitment to advancing healthcare and help improve the quality of life of hemophilia patients in our country.”